Global Diabetes Drug Market & Pipeline Insight 2015

News provided by

Apr 14, 2015, 03:21 ET

DUBLIN, April 14, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/46t7js/global_diabetes) has announced the addition of the "Global Diabetes Drug Market & Pipeline Insight 2015" report to their offering.

Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Diabetes market is a rapidly growing segment with numerous products at different stages of clinical pipeline and others at different phases of industry life cycle. Disease incidences are escalating rapidly across the globe due to which high unmet demand has been created and pharmaceutical companies are trying to provide efficient medical care to patients. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criterias set by medical regulatory authorities. Number of diabetes drugs for treatment is increasing every year due to which their market shares are expected to increase further in coming years.

Diabetes drug delivery is a mature field which provides lots of opportunities to the pharmaceutical companies to market their products. Innovation seems to be the key to success because it is quite mature and without novel functionality it doesn't seem meaningful to enter in such a competitive market segment. Increased investments in research and development segment are expected to introduce competitive products at cost effective prices in short time. It shows that the diabetes drug market segment would be filled with innovative products that would be able to offer better diabetes management to patients. In this way, it could be expected that this market would be able to grow several folds, generate significant revenues and prevent morbidity caused by diabetes.

Diabetes Indication in Report:

- Diabetic Neuropathies
- Diabetic Nephropathies
- Diabetes Mellitus
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Diabetic Foot Ulcer
- Diabetic Macular Oedema
- Diabetic Gastroparesis
- Diabetic Retinopathy
- Diabetes Insipidus
- Prediabetic State

Global Diabetes Drug Market & Pipeline Insight 2015 Report Highlights:

- Global Diabetes Drug Market Overview
- Global Diabetic Drug Clinical Pipeline by Company & Phase
- Global Diabetic Drug Clinical Pipeline: 817 Drugs
- Majority in Preclinical Phase: 205 Drugs
- Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
- Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
- Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
- Marketed Diabetic Drugs: 99 Drugs

Companies Mentioned

- AstraZeneca
- Boehringer Ingelheim
- Eli Lily
- GalaxoSmithKline
- Johnson & Johnson
- MannKind Corporation
- Merck
- Novartis
- Pfizer
- Sanofi

For more information visit http://www.researchandmarkets.com/research/46t7js/global_diabetes